Genmab Cash Pile To Grow With Another Darzalex OK
Executive Summary
The Danish biotech will be getting more revenues from its J&J-partnered multiple myeloma blockbuster following a new US approval. Analysts are impressed with the way Genmab is spending the money.
You may also be interested in...
Analysts Unconvinced By Sanofi Best-In-Class Claims For Sarclisa
Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.
BioNTech Falls Short In Jittery IPO Market
After ADC Therapeutics
Novartis Upbeat As Ofatumumab Data Delivers In MS
Novartis looks to differentiate ofatumumab from Roche's entrenched MS blockbuster Ocrevus, stressing that patients can inject the therapy at home.